[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 227
1. Conter C, Thiesse P, Delaroche E, Frachon S, Marec-Bérard P: [Multiple cystic lung lesions: a rare presentation of metastatic sarcoma]. J Radiol; 2008 Jul-Aug;89(7-8 Pt 1):895-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple cystic lung lesions: a rare presentation of metastatic sarcoma].
  • [MeSH-major] Foot Diseases / pathology. Lung Neoplasms / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male


2. Pailoor J, Iyengar KR, Chan KS, Sumithra S: Follicular dendritic cell sarcoma of inguinal lymph node--a case report. Malays J Pathol; 2008 Dec;30(2):115-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of inguinal lymph node--a case report.
  • They show varied histological features and thus can be mistaken for carcinoma or sarcoma.
  • It was excised completely and was reported as lymph node with metastatic poorly differentiated carcinoma based on Haematoxylin and eosin (H&E) stain findings.
  • The tumour cells were negative for epithelial, melanocytic, neural, leucocyte and soft tissue tumour markers.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / metabolism. Dendritic Cell Sarcoma, Follicular / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Carcinoma / pathology. Carcinoma / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Inguinal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291921.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Riggi N, Stamenkovic I: The Biology of Ewing sarcoma. Cancer Lett; 2007 Aug 28;254(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Biology of Ewing sarcoma.
  • They constitute some of the most aggressive adult and childhood cancers in that they have a high metastatic proclivity and are typically refractory to conventional chemo- and radiation therapy.
  • Ewing's sarcoma is a member of Ewing's family tumors (ESFT) and the second most common solid bone and soft tissue malignancy of children and young adults.
  • This review will highlight some of the most recent discoveries in the field of Ewing sarcoma biology and origins.
  • [MeSH-major] Sarcoma, Ewing / genetics. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetics Home Reference. consumer health - chromosome 11.
  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250957.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  • [Number-of-references] 74
  •  go-up   go-down


Advertisement
4. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S: Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res; 2009 Feb 1;15(3):1096-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to sunitinib malate in advanced alveolar soft part sarcoma.
  • PURPOSE: Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma.
  • EXPERIMENTAL DESIGN: Since July 2007, five patients with progressive metastatic ASPS have been treated with continuous SM 37.5 mg/d on a named basis.
  • [MeSH-major] Indoles / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use. Sarcoma, Alveolar Soft Part / drug therapy
  • [MeSH-minor] Adult. Drug Evaluation. Female. Humans. Male. Middle Aged. Phosphorylation. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases


5. Kasper B, Schmitt T, Wuchter P, Dimitrakopoulou-Strauss A, Ho AD, Egerer G: The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar Drugs; 2009;7(3):331-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
  • BACKGROUND: We used 2-deoxy-2-[(18)F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, Trabectedin, Yondelis).
  • PATIENTS AND METHODS: The pilot study included nine patients with metastatic STS receiving a minimum of one cycle of treatment with trabectedin.
  • [MeSH-major] Dioxoles / therapeutic use. Positron-Emission Tomography / methods. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Metastasis. Pilot Projects. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Mar;231(3):380-6 [10714631.001]
  • [Cites] Onkologie. 2008 Mar;31(3):107-12 [18322413.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):231-42 [11234874.001]
  • [Cites] J Nucl Med. 2001 May;42(5):713-20 [11337565.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3156-64 [12118030.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2012-20 [12957455.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Onkologie. 2004 Feb;27(1):23-30 [15007245.001]
  • [Cites] Nucl Med Commun. 2004 May;25(5):433-8 [15100500.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1480-7 [15347714.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50 [2013803.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] J Nucl Med. 1997 Nov;38(11):1818-23 [9374364.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3481-7 [9396401.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):250-4 [9476930.001]
  • [Cites] Eur J Nucl Med. 1999 Jun;26(6):599-605 [10369945.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):286-94 [15650639.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5420-3 [16109999.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):369-73 [16721133.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • (PMID = 19841717.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 114899-77-3 / trabectedin
  • [Other-IDs] NLM/ PMC2763103
  • [Keywords] NOTNLM ; RECIST / fluorodeoxyglucose / positron emission tomography / soft tissue sarcoma / trabectedin
  •  go-up   go-down


6. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM, European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol; 2010 Apr 01;28(10):1772-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma typically carrying a translocation between chromosomes 17 and 22 that generates functional platelet-derived growth factor B (PDGFB).
  • PATIENTS AND METHODS: Two distinct phase II trials of imatinib (400 to 800 mg daily) in patients with locally advanced or metastatic DFSP were conducted and closed prematurely, one in Europe (European Organisation for Research and Treatment of Cancer [EORTC]) with 14-week progression-free rate as the primary end point and the other in North America (Southwest Oncology Group [SWOG]) with confirmed objective response rate as the primary end point.
  • [MeSH-minor] Adult. Aged. Benzamides. Clinical Trials, Phase II as Topic. Drug Administration Schedule. Early Termination of Clinical Trials. Female. Humans. Imatinib Mesylate. Male. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1999 Nov;72(3):178-80 [10562366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5 [16407111.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2711-20 [10870053.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):696-704 [11034249.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):47-52 [11272901.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):354-60 [11291071.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2965-75 [11420709.001]
  • [Cites] Cytogenet Cell Genet. 2001;92(3-4):192-5 [11435686.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5778-83 [11479215.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3586-91 [12202658.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):623-6 [12209598.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):27-39 [12502925.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):1-12 [12550751.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1118-22 [14597453.001]
  • [Cites] Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2072-6 [14606355.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2383-95 [14633610.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1008-16 [14983497.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):341-5 [15028319.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):438-44 [15070606.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 6):30-6 [15176002.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):235-7 [15270901.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Arch Otolaryngol. 1984 Jun;110(6):398-404 [6721783.001]
  • [Cites] Surg Gynecol Obstet. 1986 May;162(5):449-52 [3704900.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2154-61 [2804904.001]
  • [Cites] CA Cancer J Clin. 1992 Mar-Apr;42(2):116-25 [1540852.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):241-8 [1607035.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Aug;76(1):1-9 [8076341.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2400-3 [7757993.001]
  • [Cites] Int J Dermatol. 1995 Apr;34(4):256-60 [7790140.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1553-8 [7495279.001]
  • [Cites] Dermatol Surg. 1996 Jun;22(6):530-4 [8646467.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 15;89(2):175-6 [8697429.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2365-9 [8708729.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jan;15(1):73-5 [8824728.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):171-4 [8978765.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):600-13 [9344201.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1055-60 [9376187.001]
  • [Cites] Am J Dermatopathol. 1997 Dec;19(6):562-7 [9415611.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):823-7 [9531366.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):576-87 [9591728.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):187-93 [9739023.001]
  • [Cites] Oncogene. 1998 Sep 10;17(10):1313-9 [9771975.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3719-23 [10446987.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2113-20 [17468914.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):821-2 [18296418.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1757-9 [18375907.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2717-25 [18451237.001]
  • [Cites] Clin Cancer Res. 2010 Jun 15;16(12):3288-95 [20439456.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2503-8 [15503305.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):866-73 [15681532.001]
  • [Cites] Anticancer Drugs. 2005 Apr;16(4):461-6 [15746584.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):511-5 [15503291.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7669-75 [16234529.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 20194851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA42777
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC3040044
  •  go-up   go-down


7. Thway K, Fisher C, Debiec-Rychter M, Calonje E: Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. Hum Pathol; 2009 Nov;40(11):1586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma.
  • Low-grade fibromyxoid sarcoma is a soft tissue sarcoma with recurrent and low metastatic potential, which has characteristic FUS-CREB3L2 or FUS-CREB3L1 fusions.
  • Low-grade fibromyxoid sarcoma and perineurioma can appear morphologically similar, particularly in small biopsy specimens, and distinction between the 2 entities is important for appropriate treatment.
  • Low-grade fibromyxoid sarcoma is negative for most immunohistochemical markers, whereas perineuriomas stain variably for epithelial membrane antigen, CD34 and claudin-1, a tight-junction associated protein.
  • We studied 15 cases of genetically proven low-grade fibromyxoid sarcoma that at least focally resembled perineurioma, with antibodies to claudin-1 and epithelial membrane antigen.
  • This has implications toward the accurate diagnosis of both tumors, and, as positivity for claudin-1 in low-grade fibromyxoid sarcoma is not previously documented, suggests that there might be underdiagnosis of low-grade fibromyxoid sarcoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Fibrosarcoma / pathology. Membrane Proteins / biosynthesis. Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Claudin-1. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucin-1 / biosynthesis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540561.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 0 / Mucin-1
  •  go-up   go-down


8. Kasper B, Gil T, Awada A: Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol; 2007 Jul;19(4):336-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
  • PURPOSE OF REVIEW: We give an overview on the emerging compounds for patients with soft tissue sarcoma.
  • RECENT FINDINGS: Soft tissue sarcomas are a heterogeneous group of tumours that arise predominantly from the embryonic mesoderm.
  • They account for fewer than 1% of all adult malignancies.
  • The prognosis of patients with advanced metastatic soft tissue sarcoma remains poor, with disease-free survival at 5 years below 10%.
  • SUMMARY: Understanding of the molecular biology and pathogenesis of soft tissue sarcomas has been enhanced, and in the near future this should translate into molecular tumour characterization and development of new therapeutic strategies.
  • [MeSH-major] Sarcoma / drug therapy


9. Sleijfer S, Seynaeve C, Verweij J: Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist; 2005 Nov-Dec;10(10):833-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.
  • The group of soft tissue sarcomas in adult patients is a heterogeneous group with more than 40 different subtypes.
  • While local treatment remains the mainstay for localized disease, systemic chemotherapy can importantly contribute in the treatment of advanced soft tissue sarcoma.
  • For patients with metastatic disease, chemotherapy is a palliative treatment in the vast majority of the cases.
  • This review addresses the current available data on chemotherapy for adult patients with soft tissue sarcoma, excluding gastrointestinal stromal tumor, the Ewing-like sarcomas, and other small blue round cell tumors.
  • In addition, it is increasingly recognized that future research in soft tissue sarcoma should focus on the identification of tumor factors that can serve as targets for treatment and that the diverse tumor subtypes should be analyzed separately for their sensitivity to systemic treatment.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314294.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Number-of-references] 50
  •  go-up   go-down


10. Ryzewicz M, McLoughlin HA, Freudenberger C, Williams A, Lindeque B: Unusual metastases from extremity soft tissue sarcomas. Orthopedics; 2008 May;31(5):439
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual metastases from extremity soft tissue sarcomas.
  • The most common metastatic route for extremity soft-tissue sarcomas is via the venous system to the lungs.
  • Metastases to other sites such as the brain, liver, and soft tissue distant from the primary tumor are rare.
  • A tumor registry, prospectively kept since 1986, was reviewed for unusual metastatic spread.
  • Of 3671 tumors, 346 high-grade extremity soft-tissue sarcomas were evaluated.
  • Based on these findings, a different strategy for follow-up of patients after treatment of a high-grade extremity soft-tissue sarcoma is suggested.
  • [MeSH-major] Extremities. Risk Assessment / methods. Sarcoma / epidemiology. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Colorado / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Rare Diseases. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292327.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Binh MB, Guillou L, Hostein I, Château MC, Collin F, Aurias A, Binh BN, Stoeckle E, Coindre JM: Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol; 2007 Oct;31(10):1557-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In about 5% cases, the dedifferentiated component is an heterologous sarcoma such as leiomyosarcoma or rhabdomyosarcoma.
  • Moreover, DLPS with a myogenic component have a low metastatic potential, similar to conventional DLPS and significantly lower to the metastatic potential of leiomyosarcomas.
  • [MeSH-major] Leiomyosarcoma / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology. Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase 4 / genetics. Cyclin-Dependent Kinase 4 / metabolism. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Nucleic Acid Amplification Techniques. Proto-Oncogene Proteins c-mdm2 / genetics. Proto-Oncogene Proteins c-mdm2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895758.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


12. Huang W, Zhang X, Li D, Chen J, Meng K, Wang Y, Lu Z, Zhou X: Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts. Virchows Arch; 2006 Feb;448(2):200-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts.
  • Clear cell sarcoma is a high-grade sarcoma with morphological features resembling those of malignant melanoma.
  • An osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts is very rare.
  • Herein, we report an unusual stomach tumor with microscopic and immunohistochemical characteristics of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • The differential diagnosis included gastrointestinal stromal tumor, primary or metastatic melanoma, and epithelioid malignant peripheral nerve sheath tumor.
  • To the best of our knowledge, this is possibly the second description of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Osteoclasts / pathology. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Diagnosis, Differential. Giant Cells / chemistry. Giant Cells / pathology. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1042-4 [10570398.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):438-40 [10705403.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] Arch Pathol Lab Med. 2002 Aug;126(8):972-4 [12171499.001]
  • [Cites] Pathologica. 1998 Aug;90(4):388-90 [9793400.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):75-81 [12754623.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4424-7 [9751528.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):969-75 [10491522.001]
  • [Cites] Histopathology. 1993 Mar;22(3):255-9 [7684355.001]
  • [Cites] J Clin Pathol. 2001 Feb;54(2):96-102 [11215292.001]
  • [Cites] Indian J Gastroenterol. 1999 Oct-Nov;18(4):176 [10531723.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):121-4 [9422325.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] Gen Diagn Pathol. 1996 Jun;142(1):63-7 [8793489.001]
  • [Cites] Am Surg. 1992 Jul;58(7):418-22 [1616187.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Histopathology. 2002 Dec;41(6):526-30 [12460205.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • (PMID = 16220298.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


13. Kim YD, Lee CH, Lee MK, Jeong YJ, Kim JY, Park DY, Sol MY: Primary alveolar soft part sarcoma of the lung. J Korean Med Sci; 2007 Apr;22(2):369-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma of the lung.
  • Alveolar soft part sarcoma (ASPS) is a rare epithelial-like soft tissue sarcoma.
  • Primary pulmonary involvement of this sarcoma, without evidence of soft tissue tumor elsewhere, is very exceptional.
  • After 5 months, three metastatic lesions, involving lumbar vertebrae and occipital scalp, were found.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / radiography. Pulmonary Alveoli / pathology. Pulmonary Alveoli / radiography. Sarcoma / pathology. Sarcoma / radiography
  • [MeSH-minor] Adult. Female. Humans. Rare Diseases / pathology. Rare Diseases / radiography. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / radiography

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):319-23 [10838498.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):179-92 [11438465.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):771-7 [1812692.001]
  • [Cites] Hum Pathol. 1993 Sep;24(9):1030-4 [8253458.001]
  • [Cites] Ann Pathol. 1996;16(1):49-52 [8652002.001]
  • [Cites] Adv Anat Pathol. 1999 May;6(3):125-39 [10342010.001]
  • (PMID = 17449953.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693611
  •  go-up   go-down


14. Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs; 2005;65(2):167-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
  • The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • Small round cell tumours (SRCTs), such as Ewing's sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease.
  • Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In relapsed 'adult type' soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile.
  • A high activity has been reported for the taxanes, in particular for paclitaxel, in vascular sarcomas located in the scalp or face and in Kaposi's sarcoma.
  • It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited.
  • Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology


15. Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ: Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer; 2008 Sep;44(13):1841-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas.
  • PURPOSE: To identify the risk of lung metastases at the time of diagnosis in patients with soft tissue sarcomas (STS) and to establish the optimum imaging strategy for the diagnosis of these metastases and whether this affects outcome.
  • The patient demographics, tumour type, size, depth, histology grade and presence of metastatic disease at presentation were studied.
  • We estimated the efficacy of CXR in identifying pulmonary metastatic disease compared with CT chest and whether this affected patient survival.
  • [MeSH-major] Lung Neoplasms / secondary. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Child, Preschool. Humans. Infant. Middle Aged. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Survival Analysis. Tomography, X-Ray Computed. Unnecessary Procedures. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640829.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Sugino K, Kishi K, Takaya H, Miyamoto A, Fujii T, Yoshimura K: [A case of Ewing's sarcoma of the right femur associated with pulmonary metastases detected by fluorodeoxyglucose positron emission tomography]. Nihon Kokyuki Gakkai Zasshi; 2008 Jul;46(7):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Ewing's sarcoma of the right femur associated with pulmonary metastases detected by fluorodeoxyglucose positron emission tomography].
  • Ewing's sarcoma gene rearrangement was found using fluorescence in situ hybridization on frozen-section specimens.
  • Based on these findings, a diagnosis of Ewing's sarcoma was made.
  • In cases of multiple pulmonary nodular lesions in a young patient, metastatic tumors arising from bone soft tissue should be included in the differential diagnosis.
  • [MeSH-major] Femoral Neoplasms / pathology. Femoral Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / secondary. Positron-Emission Tomography. Sarcoma, Ewing / pathology. Sarcoma, Ewing / radionuclide imaging
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700576.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Rehders A, Peiper M, Stoecklein NH, Alexander A, Boelke E, Knoefel WT, Rogiers X: Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J Surg; 2009 Jan;33(1):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for soft-tissue sarcomas: is it justified?
  • BACKGROUND: Except for patients with gastrointestinal stromal tumors (GIST), systemic chemotherapy in patients with liver metastasis of soft-tissue sarcoma (STS) is not effective.
  • RESULTS: Twenty-seven of 45 patients with liver metastasis underwent hepatic resection; 59% of these patients had a solitary metastasis, 22% had two metastases, and 18% had three or more metastatic nodules.
  • [MeSH-major] Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2004 Sep 1;87(3):116-20 [15334637.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2719-25 [12860950.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):158-71 [16041205.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):70-2 [10025385.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1613-7 [16247574.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jun;35(6):338-41 [15928191.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:50-7 [10429623.001]
  • [Cites] Hepatology. 1996 Dec;24(6):1386-91 [8938166.001]
  • [Cites] Cancer. 2004 May 15;100(10):2233-9 [15139069.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2676-84 [10894866.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):982-99 [16538219.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(1):77-80 [12827476.001]
  • [Cites] Hepatology. 1995 May;21(5):1317-21 [7737637.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):389-95 [10023707.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • (PMID = 18949511.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cil T, Altintas A, Isikdogan A: Rhabdomyosarcoma presenting with destructive large lesion of the face. South Med J; 2008 Jan;101(1):104-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents.
  • Prognostic factors of RMS include tumor status, primary tumor site, localization in the organ or tissue of origin, patient age and histopathological type.
  • Alveolar histologic type is more aggressive than the other types and is seen in most patients with locally advanced and metastatic disease.
  • [MeSH-major] Facial Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176304.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Sato N, Morioka H, Yabe H: Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol Rep; 2008 Jan;19(1):129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis.
  • Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults.
  • Despite intensive treatments for patients with ESFT, disease which presents with metastatic spread or relapses after primary treatment remains incurable in the majority of cases, indicating the importance of efforts to develop new treatment modalities, including immunotherapy.
  • Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction


20. Manoso MW, Frassica DA, Deune EG, Frassica FJ: Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol; 2005 Sep 1;91(3):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas.
  • BACKGROUND AND OBJECTIVES: Unplanned excisions of soft-tissue sarcomas of the extremities occur commonly.
  • Our goal was to evaluate the presence of residual disease, the treatment outcomes as they relate to local and distant recurrence and 5-year survival, and the limb functional outcomes in patients with unplanned sarcoma excision who were treated with re-excision and adjuvant therapy.
  • METHODS: Between 1993 and 1999, 42 patients presented to our institution after unplanned excision of soft-tissue sarcomas.
  • Of those 42 patients, 38 without gross residual disease or metastatic lesions formed the basis of this review.
  • Univariate analysis showed that stage-III disease (American Joint Committee on Cancer classification of soft-tissue sarcomas), lesions below the fascia, a histologic high-grade, and the development of organ metastasis were statistically significant factors for mortality.
  • Stage-III disease also was significant for mortality on multivariate analysis.
  • Only stage-III disease was significant for the development of local recurrence.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Baltimore / epidemiology. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Reoperation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118773.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Witte D, Bernd L, Bruns J, Gosheger G, Hardes J, Hartwig E, Lehner B, Melcher I, Mutschler W, Schulte M, Tunn PU, Wozniak W, Zahlten-Hinguranage A, Zeifang F: Limb-salvage reconstruction with MUTARS hemipelvic endoprosthesis: a prospective multicenter study. Eur J Surg Oncol; 2009 Dec;35(12):1318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was, in 29 cases, a primary bone or soft tissue sarcoma, in 11 patients, a metastasis.
  • Seventeen of them had a primary tumour, eight a metastatic malignancy.
  • The indication for hemipelvic prosthesis in patients with a metastatic disease must be considered seriously.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Prospective Studies. Prosthesis Implantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477098.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


22. Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS: Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience. Acta Oncol; 2009;48(8):1165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hospital sarcoma database and patient records were reviewed to identify cases with synchronous or metachronous skeletal osteosarcoma.
  • Patients with more than one skeletal lesion in the absence of pulmonary or other soft tissue tumor manifestations were included in the study, and histopathological slides from these tumors were reviewed.
  • Thirteen patients are dead, 11 from metastatic osteosarcoma, one from myelodysplastic syndrome, and one from wound infection and methotrexate-related nephrotoxicity; whereas three patients are still alive with no evidence of osteosarcoma.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863225.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Picciotto F, Zaccagna A, Derosa G, Pisacane A, Puiatti P, Colombo E, Dardano F, Ottinetti A: Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy. Eur J Dermatol; 2005 Jan-Feb;15(1):46-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy.
  • Clear cell sarcoma of the tendons and aponeuroses is an aggressive, rare soft tissue tumour that occurs predominantly in the extremities of young adults.
  • Although it appears to be histogenetically related to melanoma, its clinical behaviour resembles soft tissue sarcoma.
  • We describe a case of clear cell sarcoma of the hand and evaluate the feasibility of the sentinel lymph node biopsy (SLNB) technique in this kind of tumour.
  • Up to now, there are no reports that describe the use of SLNB in clear cell sarcoma.
  • Histological examination of the lymphnode allowed identification of metastatic cells and thus provide for radical lymphadenectomy.
  • [MeSH-major] Hand. Sarcoma, Clear Cell / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701594.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Singh RP, Grimer RJ, Bhujel N, Carter SR, Tillman RM, Abudu A: Adult head and neck soft tissue sarcomas: treatment and outcome. Sarcoma; 2008;2008:654987
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult head and neck soft tissue sarcomas: treatment and outcome.
  • We have retrospectively analysed the experience of a musculoskeletal oncological unit in the management of adult head and neck soft tissue sarcomas from 1990 to 2005.
  • 42% of the patients developed local recurrence and 42% developed metastatic disease usually in the lungs.
  • Adult head and neck soft tissue sarcomas have a high mortality rate with a high risk of local recurrence and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Aug 15;89(4):868-72 [10951351.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):377-88, vii [11370499.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):379-417 [12916461.001]
  • [Cites] World J Surg. 2003 Jul;27(7):875-83 [14509522.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):619-28 [15172935.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):259-63 [15923798.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Laryngoscope. 2006 May;116(5):780-5 [16652087.001]
  • [Cites] Head Neck. 2007 Aug;29(8):731-40 [17274049.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):697-702 [8033050.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):981-6 [8074826.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Head Neck. 2005 Oct;27(10):916-22 [16136585.001]
  • (PMID = 18382622.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2276692
  •  go-up   go-down


25. Suemitsu R, Yoshino I, Tomiyasu M, Ondo K, Ueda H, Iwamoto Y, Maehara Y: Outcome of a pulmonary metastasectomy for an orthopedic malignancy. Jpn J Thorac Cardiovasc Surg; 2005 Aug;53(8):420-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to examine the pulmonary metastatic results in patients with orthopedic malignancies.
  • The survival following the resection of a pulmonary metastatic tumor was then analyzed using the Kaplan-Meier method.
  • CONCLUSION: Pulmonary metastasis from soft tissue tumors is considered to lead to a poor prognosis for younger patients and a metastasectomy for such patients should be considered as one of the potentially effective treatments.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy / mortality. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 1988;2(1):37-42 [3272197.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 May;15(5):592-6 [10386402.001]
  • [Cites] Ann Surg. 1999 May;229(5):602-10; discussion 610-2 [10235518.001]
  • [Cites] Chest Surg Clin N Am. 1998 Feb;8(1):77-95 [9515174.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1644-51 [8156491.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):662-8 [1730117.001]
  • [Cites] Thorax. 1991 Oct;46(10):727-31 [1750020.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1919-25 [8364869.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Ann Thorac Surg. 1983 Nov;36(5):516-23 [6579887.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1407-11 [1365685.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):184-90; discussion 190-1 [10945362.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):245-54 [9010097.001]
  • (PMID = 16164253.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Sharma S, Turcotte RE, Isler MH, Wong C: Cemented rotating hinge endoprosthesis for limb salvage of distal femur tumors. Clin Orthop Relat Res; 2006 Sep;450:28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 67 bone sarcomas, two soft tissue sarcomas and eight metastatic carcinomas.
  • There were five local recurrences; three needed amputation and two soft-tissue excisions only.
  • [MeSH-major] Femoral Neoplasms / surgery. Limb Salvage. Prostheses and Implants. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Cementation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prosthesis Design. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906068.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE: A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol; 2006 Nov;58(5):634-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
  • We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma.
  • EXPERIMENTAL DESIGN: Informed consent was obtained from patients with metastatic soft tissue sarcoma naïve to systemic chemotherapy (adjuvant chemotherapy allowed).
  • Immunohistochemical estimation of MGMT expression from archival tissue ranged from 20 to 99% positive staining cells.
  • Further development of this regimen and dose for the treatment of soft tissue sarcoma is not warranted due to the lack of objective responses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Carmustine / administration & dosage. Carmustine / adverse effects. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / adverse effects. Female. Gastrointestinal Stromal Tumors / drug therapy. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Immunohistochemistry. Infant. Injections, Intravenous. Leiomyosarcoma / drug therapy. Male. Middle Aged. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Survival Analysis. Tachycardia, Supraventricular / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520986.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA63187
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


28. Fox BD, Patel A, Suki D, Rao G: Surgical management of metastatic sarcoma to the brain. J Neurosurg; 2009 Jan;110(1):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of metastatic sarcoma to the brain.
  • OBJECT: Metastatic sarcoma to the brain is rare and represents a therapeutic challenge due to its relative resistance to radio- and chemotherapy.
  • The authors reviewed a series of patients with metastatic sarcoma to the brain treated surgically to determine outcomes and identify predictors of survival in these patients.
  • METHODS: A retrospective review of prospectively collected data was undertaken on patients undergoing surgery between 1993 and 2005 for metastatic sarcoma to the brain at The University of Texas, M.D.
  • RESULTS: During the study period, 62 patients underwent 84 operations for metastatic sarcoma to the brain.
  • In multivariate and univariate analysis, control of systemic disease, and sarcomas originating from bone, cartilage, or soft tissue were predictors of survival.
  • In patients with alveolar soft-part sarcoma, there was a significantly increased survival advantage compared with all other histological subgroups.
  • CONCLUSIONS: The authors' results suggest that in selected patients, resection of metastatic sarcoma to the brain is associated with a relatively low risk of operative death and results in improvement in neurological function.
  • Patients with systemic control of their primary disease and certain histological subtypes (specifically alveolar soft-part sarcoma) have improved overall and progression-free survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neurosurgical Procedures. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult


29. Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A: Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs; 2009 Jan;20(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
  • Doxorubicin and ifosfamide are currently considered the cornerstones of treatment for advanced soft tissue sarcomas (STSs).
  • Of the 11 patients, seven received no earlier systemic therapy for their sarcoma.
  • PLD is active and safe for long-term treatment of metastatic STSs and may be important in maintaining response.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / analogs & derivatives. Polyethylene Glycols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342997.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


30. Kontogeorgakos VA, Martinez S, Dodd L, Brigman BE: Extremity soft tissue sarcomas presented as hematomas. Arch Orthop Trauma Surg; 2010 Oct;130(10):1209-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremity soft tissue sarcomas presented as hematomas.
  • INTRODUCTION: Soft tissue sarcoma (STS) with extensive intra-tumoral hemorrhage is an infrequently described entity, usually misdiagnosed as intra-muscular hematoma.
  • MATERIALS AND METHODS: We retrospectively identified 15 patients, with initial clinical or imaging diagnosis of hematoma, or hematoma versus hemorrhagic sarcoma, although final diagnosis of high-grade STS was established in all cases.
  • Ten patients were referred for further evaluation with the initial diagnosis of muscle strain/hematoma, hematoma versus abscess in one, whereas four were referred for soft tissue mass evaluation.
  • One patient had lung metastatic disease at presentation and eight developed lung metastases within a median time of 7 months.
  • The evacuation of hematomas should include pathologic examination of tissue.
  • Prognosis is dismal due to early metastatic disease.
  • [MeSH-major] Hematoma / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Hemangiosarcoma / diagnosis. Histiocytoma, Malignant Fibrous / diagnosis. Humans. Male. Middle Aged. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Sarcoma, Synovial

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838719.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Bien E, Kazanowska B, Dantonello T, Adamkiewicz-Drozynska E, Balcerska A, Madziara W, Rybczynska A, Nurzynska-Flak J, Solarz E, Kurylak A, Zalewska-Szewczyk B, Krawczyk M, Izycka-Swieszewska E, Rapala M, Koscielniak E: Factors predicting survival in childhood malignant and intermediate vascular tumors : retrospective analysis of the Polish and German cooperative paediatric soft tissue sarcoma study groups and review of the literature. Ann Surg Oncol; 2010 Jul;17(7):1878-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting survival in childhood malignant and intermediate vascular tumors : retrospective analysis of the Polish and German cooperative paediatric soft tissue sarcoma study groups and review of the literature.
  • METHODS: A total of 32 children with malignant vascular tumors (14 angiosarcomas [AS], 5 epithelioid hemangioendotheliomas, and 13 intermediate vascular tumors, including other hemangioendotheliomas plus adult-type hemangiopericytomas), registered in the German and Polish Paediatric Soft Tissue Sarcomas Study Groups, were treated following the Cooperative Weichteilsarkom Studiengruppe (CWS)-81, -86, -91, and -96 protocols.
  • An urgent need for modification of systemic therapy is needed because of the development of many metastatic and/or combined relapses and poor response to classic chemotherapy.
  • [MeSH-major] Hemangioendothelioma / mortality. Hemangiopericytoma / mortality. Hemangiosarcoma / mortality. Sarcoma / mortality. Vascular Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Poland / epidemiology. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20333551.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


32. Coindre JM: Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med; 2006 Oct;130(10):1448-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of soft tissue sarcomas: review and update.
  • CONTEXT: Histologic grading is the most important prognostic factor and the best indicator of metastatic risk in adult soft tissue sarcomas.
  • However, grading is useful in more than 90% of adult soft tissue sarcomas and has been adapted to pediatric nonrhabdomyosarcomatous sarcomas.
  • OBJECTIVE: To review the current value and limitations of histologic grading in soft tissue sarcomas.
  • DATA SOURCES: The reviews on grading and original studies on prognostic factors in soft tissue sarcomas were analyzed.
  • CONCLUSIONS: Grading is the best predictor of metastasis outcome in adult soft tissue sarcomas and should be part of the pathologic report.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090186.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


33. Baxter BT, Mahoney C, Johnson PJ, Selmer KM, Pipinos II, Rose J, Neff JR: Concomitant arterial and venous reconstruction with resection of lower extremity sarcomas. Ann Vasc Surg; 2007 May;21(3):272-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Limb salvage can now be achieved in many cases of lower extremity sarcoma.
  • All of the adults except one had soft tissue sarcomas; the resected vessels were reconstructed with contralateral saphenous vein.
  • Three patients died of metastatic disease, and one died from a postoperative pulmonary embolism.
  • Two patients ultimately required above-knee amputation: one child for tissue loss secondary to reperfusion injury, and one adult because of graft thrombosis secondary to progression of peripheral arterial disease.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Lower Extremity / blood supply. Lower Extremity / pathology. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Arteries / pathology. Arteries / surgery. Child. Female. Follow-Up Studies. Humans. Male. Reconstructive Surgical Procedures. Retrospective Studies. Stockings, Compression. Survival Analysis. Time Factors. Treatment Outcome. Veins / pathology. Veins / surgery. Walking

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484959.001).
  • [ISSN] 0890-5096
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W: Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol; 2006 Dec;13(12):1655-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FN SLN biopsy results correlated with primary tumor thickness >4 mm (P = .0012), primary tumor ulceration (P = .0002), primary tumor level of invasion Clark stage IV/V (P = .0005), and nodular melanoma histological type (P = .0375).
  • The FN group was characterized by a higher ratio of two or more metastatic nodes and extracapsular involvement of lymph nodes after LND compared with the CLND group (P < .0001 and P < .0001, respectively).
  • Additional detailed pathological review of FN SLN revealed metastatic disease in 14 patients, which decreased the SLN biopsy failure rate to 4.4% (43 of 979).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. False Negative Reactions. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016755.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH: Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer; 2009 Jan 15;9:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of alveolar soft-part sarcoma (ASPS).
  • BACKGROUND: Alveolar soft-part sarcoma (ASPS) is an extremely rare, highly vascular soft tissue sarcoma affecting predominantly adolescents and young adults.
  • METHODS: For seven patients with confirmed primary or metastatic ASPS, RNA samples were isolated immediately following surgery, reverse transcribed to cDNA and each sample hybridized to duplicate high-density human U133 plus 2.0 microarrays.


36. Innocenti M, Abed YY, Beltrami G, Delcroix L, Balatri A, Capanna R: Quadriceps muscle reconstruction with free functioning latissimus dorsi muscle flap after oncological resection. Microsurgery; 2009;29(3):189-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reconstruction of the total or partial loss of quadriceps muscle after soft tissue sarcomas excision with free functioning latissimus dorsi muscle transfer had become more popular in the last years.
  • Three patients (27.3%) died of metastatic disease.
  • Microsurgical reconstruction of soft tissue sarcoma helps to expand the indications of limb salvage by allowing better local control and achieving adequate function and coverage.
  • [MeSH-major] Microsurgery / methods. Muscle Neoplasms / surgery. Quadriceps Muscle. Sarcoma / surgery. Surgical Flaps. Tissue and Organ Harvesting / methods
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Male. Middle Aged. Recovery of Function. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] Microsurgery. 2009;29(7):584-5 [19530084.001]
  • (PMID = 19097058.001).
  • [ISSN] 1098-2752
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D'Angelo P, Di Cataldo A, Carli M: The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer; 2005 Apr 15;103(8):1719-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
  • BACKGROUND: The role of doxorubicin (Doxo) as part of multidrug regimens used to treat children with soft tissue sarcoma (STS) is controversial.
  • To evaluate the feasibility of combining Doxo with the well established ifosfamide, vincristine, and actinomycin D (IVA) regimen, the Italian STS Committee performed a pilot study on a series of children with metastatic STS.
  • This combination will be investigated in high-risk patients with rhabdomyosarcoma in a randomized trial launched by the European pediatric Soft tissue sarcoma Study Group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Pilot Projects. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15754335.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


38. Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S: A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process? Saudi Med J; 2005 Aug;26(8):1190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
  • OBJECTIVE: Within soft-tissue sarcoma, primitive neuroectodermal tumors have been shown to cover a wide spectrum of small round cell sarcomas, including Ewing's sarcomas (ES) and primitive neuroectodermal tumors (PNET).
  • Five were diagnosed as metastatic disease whereas 23 were diagnosed as non-metastatic disease at admission.
  • There was no significant correlation between c-kit expression and gender, localization, metastatic status, treatment modalities and tumor.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / metabolism. Neuroectodermal Tumors, Primitive / pathology. Proto-Oncogene Proteins c-kit / metabolism. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Protein-Tyrosine Kinases / antagonists & inhibitors. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127511.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


39. Montebugnoli L, Venturi M, Gissi DB, Flamminio F, Foschini MP: Low-grade myofibroblastic sarcoma of the gingiva. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade myofibroblastic sarcoma of the gingiva.
  • Low-grade myofibroblastic sarcoma is a malignant tumour from myofibroblasts, which has only recently become clearly defined.
  • It represents a rare entity developing in the soft tissues of the head and neck.
  • There was no sign of recurrence or metastatic disease during the 18-month postoperative period.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Mandibular Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Gingiva / pathology. Gingiva / surgery. Humans. Male. Osteotomy. Positron-Emission Tomography. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):119-20 [14767203.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct;104(4):530-9 [17142072.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Nov;104(5):e52-8 [17964473.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Aug;108(2):248-54 [19615664.001]
  • (PMID = 22797208.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029420
  •  go-up   go-down


40. Tsakonas GP, Kallistratos MS, Balamoti EK, Gassiamis A, Zizi-Sermpetzoglou A, Mylonakis N, Karabelis A, Kosmas C: Rare and aggressive metastatic, axial multifocal local epithelioid sarcoma associated with paraneoplastic granulocytosis and hypoglycaemia. Lancet Oncol; 2007 Jan;8(1):82-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and aggressive metastatic, axial multifocal local epithelioid sarcoma associated with paraneoplastic granulocytosis and hypoglycaemia.
  • [MeSH-major] Granulocytes / pathology. Hypoglycemia. Paraneoplastic Syndromes. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy


41. Liu Y, Zheng H, Liu Y, Fang K: Metastatic epithelioid sarcoma. Eur J Dermatol; 2007 May-Jun;17(3):249-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic epithelioid sarcoma.
  • [MeSH-major] Lung Neoplasms / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Ankle / pathology. Epithelioid Cells / pathology. Female. Humans. Skin Ulcer / etiology


42. Mocellin S, Rossi CR, Brandes A, Nitti D: Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev; 2006 Feb;32(1):9-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
  • The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two decades based on the results from randomized controlled trials, which are guiding physicians in the treatment decision-making process.
  • Despite significant improvements in the control of local disease, a significant number of patients ultimately die of recurrent/metastatic disease following radical surgery due to a lack of effective adjuvant treatments.
  • In addition, the characteristic chemoresistance of STS has compromised the therapeutic value of conventional antineoplastic agents in cases of unresectable advanced/metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Sarcoma / metabolism. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant. Enzyme Inhibitors / therapeutic use. Genetic Therapy. Growth Substances / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338075.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / Enzyme Inhibitors; 0 / Growth Substances; 0 / Matrix Metalloproteinase Inhibitors
  • [Number-of-references] 234
  •  go-up   go-down


43. Flannery T, Kano H, Niranjan A, Monaco EA 3rd, Flickinger JC, Kofler J, Lunsford LD, Kondziolka D: Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases. Int J Radiat Oncol Biol Phys; 2010 Feb 1;76(2):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary pathology was metastatic leiomyosarcoma (4 patients), osteosarcoma (3 patients), soft-tissue sarcoma (5 patients), chondrosarcoma (2 patients), alveolar soft part sarcoma (2 patients), and rhabdomyosarcoma, Ewing's sarcoma, liposarcoma, neurofibrosarcoma, and synovial sarcoma (1 patient each).
  • [MeSH-major] Brain Neoplasms / surgery. Radiosurgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19467792.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Altan E, Bitik B, Kalpakci Y, Dogan E, Altundag K: Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. J Altern Complement Med; 2009 Feb;15(2):113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee.
  • [MeSH-major] Drug-Induced Liver Injury / etiology. Nerium / adverse effects. Plant Extracts / adverse effects. Sarcoma, Synovial. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Injections, Intramuscular. Knee Joint. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216656.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


45. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 1981 May 15;47(10):2422-9 [7272896.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Ter. 1998 Mar-Apr;149(2):121-5 [9780476.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


46. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ, Lev D: Angiosarcoma: clinical and molecular insights. Ann Surg; 2010 Jun;251(6):1098-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Angiosarcoma (AS) is a rare understudied soft tissue sarcoma exhibiting endothelial cell differentiation.
  • An AS tissue microarray (n = 68 human specimens) was constructed for immunohistochemical analysis of multiple potential drugable kinase-related molecular markers.
  • RESULTS: Forty-three (19.4%) metastatic AS patients and 179 patients (80.6%) with localized disease were included.
  • Median survival of localized versus metastatic AS was 49 (range, 2-188) versus 10 (range, 1-69) months (P < 0.0001).
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Biomarkers, Tumor / analysis. Combined Modality Therapy. DNA-Binding Proteins / metabolism. Female. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Phosphoproteins / metabolism. Phosphotransferases / antagonists & inhibitors. Prognosis. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Epidermal Growth Factor / metabolism. Survival Rate. Transcription Factors / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ISOXABEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485141.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138345
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / EIF4EBP1 protein, human; 0 / ELF4 protein, human; 0 / Phosphoproteins; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 82558-50-7 / isoxaben; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


47. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, Steadman P: Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg; 2006 Mar;76(3):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical margin and its influence on survival in soft tissue sarcoma.
  • BACKGROUND: The goal of surgeons treating soft tissue sarcoma is to gain local control, to avoid risk of local recurrence and to avoid compromise of the patient's potential survival.
  • METHODS: Two hundred and seventy-nine patients who presented with soft tissue sarcoma without metastatic disease were analysed.
  • RESULTS: The extent of the surgical margin was not clinically or statistically significant in the development of metastatic disease.
  • [MeSH-major] Sarcoma / mortality. Sarcoma / surgery. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2006 Mar;76(3):97 [16626338.001]
  • (PMID = 16626341.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


48. Alford SH, Vrana MS, Waite L, Heim-Hall J, Sylvia VL, Williams RP: Matrix metalloproteinase expression in high grade soft tissue sarcomas. Oncol Rep; 2007 Dec;18(6):1529-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase expression in high grade soft tissue sarcomas.
  • Soft tissue sarcomas comprise a heterogeneous group of mesenchymal tumors with varying biological behavior ranging from indolent tumors with no or minimal metastatic risk to aggressive and frequently metastasizing tumors.
  • Among the more common aggressive adult soft tissue sarcomas are malignant fibrous histiocytoma, synovial sarcoma and liposarcoma.
  • Matrix metalloproteinases are enzymes which perform a homeostatic role in mesenchymal tissue and function in both tumorigenesis and metastasis.
  • The objectives of this study are to determine the presence and relative quantity of matrix metalloproteinases (MMPs) -1, -2, -8, -9, and -13; extracellular matrix metalloproteinase inducer (EMMPRIN); and tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2 in high grade soft tissue sarcoma tumor specimens using real-time PCR.
  • The second objective is to determine if a relationship exists between quantity of EMMPRIN, MMPs, and TIMPs expressed in tumor tissue and disease-free survival.
  • One hundred and forty patients diagnosed with high grade soft tissue sarcomas between 1995-2003 were identified.
  • Tissue blocks and histologic slides were acquired for 41 specimens.
  • No significant differences were found between the three types of high grade soft tissue sarcomas studied and the expression of MMPs.
  • Our data support other research which finds variable correlation between MMP expression in soft tissue sarcomas and disease-free survival.
  • [MeSH-major] Sarcoma / enzymology
  • [MeSH-minor] Biopsy. Humans. Liposarcoma / enzymology. Liposarcoma / mortality. Retrospective Studies. Sarcoma, Synovial / enzymology. Sarcoma, Synovial / mortality. Survival Analysis. Time Factors. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982640.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  •  go-up   go-down


49. Hartmann JT, Patel S: New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep; 2005 Jul;7(4):300-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New drug developments for patients with metastatic soft tissue sarcoma.
  • Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies that are treated with multimodality dose-intensive neoadjuvant protocols regardless of size or overt metastatic disease.
  • However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Curr Oncol Rep. 2012 Apr;14(2):220 [22371000.001]
  • [Cites] Anticancer Drugs. 2002 May;13 Suppl 1:S7-9 [12173492.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1329-34 [11870176.001]
  • [Cites] Cancer Treat Rep. 1976 Feb;60(2):199-203 [769974.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):561-4 [12477998.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):48-51 [12694653.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1318-29 [12763223.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2848-52 [12767099.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2579-82 [11289134.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):129-32 [12003189.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Jul;9(7):1545-51 [11060759.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1899-901 [12820475.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):263-5 [7781149.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):410-2 [10448291.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1969-73 [12673725.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):453-6 [10477164.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Ann Oncol. 1995 Oct;6(8):847-9 [8589028.001]
  • [Cites] Clin Ter. 1999 Jan-Feb;150(1):17-20 [10367540.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1664-71 [15378498.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2937-47 [11387367.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2248-52 [8635028.001]
  • [Cites] Anticancer Drugs. 1999 Nov;10(10):873-7 [10630354.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Cancer. 2003 Dec 15;98 (12 ):2693-9 [14669291.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S174-9 [8453693.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] J Med Chem. 1984 Feb;27(2):196-201 [6694168.001]
  • [Cites] J Med Chem. 1986 Aug;29(8):1553-5 [3735324.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):422-3 [9640234.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 15946590.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


50. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K: Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res; 2007 Sep-Oct;27(5B):3489-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome.
  • The present study was performed to assess the efficacy of caffeine-potentiated chemotherapy for high-grade soft tissue sarcoma (STS).
  • PATIENTS AND METHODS: A non-randomised prospective clinical trial was initiated for 90 patients with non-metastatic (stages II and III) or metastatic (stage IV) STS.
  • The local recurrence rate was 23.7% in stages II and III and 13.6% in stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Caffeine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Drug Synergism. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Time Factors. Treatment Outcome


51. Taylor M, Guillon M, Champion V, Marcu M, Arnoux JB, Hartmann O: [Ewing's tumor]. Arch Pediatr; 2005 Sep;12(9):1383-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ET affects mainly bones of the central axis, and almost always involves soft tissue infiltration.
  • Intensified therapeutic strategies have for the first time cured some metastatic ET patients, but at the cost of major side effects.
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Neoadjuvant Therapy. Prognosis. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046110.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 39
  •  go-up   go-down


52. Daigeler A, Lehnhardt M, Sebastian A, Belyaev O, Steinstraesser L, Steinau HU, Kuhnen C: Metachronous bilateral soft tissue sarcoma of the extremities. Langenbecks Arch Surg; 2008 Mar;393(2):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous bilateral soft tissue sarcoma of the extremities.
  • BACKGROUND AND AIMS: Synchronous and heterochronous multiple soft tissue sarcoma of the extremities is very rare.
  • Out of 1,201 of our patients, 4 patients presented with symmetrical bilateral soft tissue sarcoma of the extremities.
  • RESULTS: All tumours were located at the extremities and were diagnosed as leiomyosarcoma in two patients, malignant fibrous histiocytoma and clear cell sarcoma in one patient each.
  • In two patients a second primary sarcoma of the same entity was considered the most likely diagnosis, whereas in one patient a contralateral lymph node metastasis and in one other patient an atypical soft tissue metastasis had to be taken into account.
  • Aside from irradiation effects, exposition to other carcinogenic agents or genetic predisposition, the reasons for the clustering of soft tissue sarcoma in one same patient remain still unclear.
  • Only one patient, although suffering from disseminated metastatic disease was living at follow-up time, the other three patients had already died.
  • CONCLUSION: The interpretation of the bilateral manifestation of soft tissue sarcoma remains open, but predicts an unfavourable outcome.
  • [MeSH-major] Extremities / surgery. Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Humans. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Lymphatic Metastasis. Male. Middle Aged. Mitotic Index. Necrosis. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Prognosis. Retrospective Studies. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2788-93 [10914725.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):532-6 [10507781.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1363-71 [11283938.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2409-12 [12174935.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1243-6 [8260380.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2633-5 [15494976.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):165-9 [9434825.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1379-85 [1365680.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):176-8 [8603807.001]
  • [Cites] J Pediatr Surg. 1995 Jul;30(7):1042-4; discussion 1044-5 [7472929.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Sep-Oct;20(5):494-7 [9787328.001]
  • [Cites] Acta Chir Scand. 1988 Jul-Aug;154(7-8):477-9 [3188797.001]
  • [Cites] Skeletal Radiol. 1988;17 (7):518-21 [2849210.001]
  • (PMID = 17242894.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Yildirim H, Metintaş M, Ak G, Dündar E, Erginel S: Soft tissue sarcoma metastatic to pleura. Tuberk Toraks; 2008;56(2):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma metastatic to pleura.
  • However, pleural metastases of soft tissue sarcoma that constitute less than 1% of adult solid malignancy are extremely rare.
  • We report a 57 year-old man who presented to us with left chest pain and progressive dyspnea and was diagnosed to have a pleural metastases of soft tissue sarcoma by thoracoscopic biopsy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Sarcoma / pathology. Thoracoscopy / methods

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tuberk Toraks. 2008;56(4):487-8; author reply 488 [19123090.001]
  • [CommentIn] Tuberk Toraks. 2008;56(4):485; author reply 486 [19123089.001]
  • (PMID = 18701980.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


54. Lim HS, Heo SH, Park JG, Kang HK: Metastatic alveolar soft part sarcoma of the breast. J Ultrasound Med; 2006 Jul;25(7):929-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic alveolar soft part sarcoma of the breast.
  • [MeSH-major] Breast Neoplasms / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798907.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


55. Kasper B, Ho AD, Egerer G: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology; 2005;68(2-3):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
  • Sarcomas represent a rare and heterogeneous disease, and the prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcomas remains poor, with a disease-free survival of less than 10% at 5 years.
  • However, all studies comprised small patient cohorts and included very heterogeneous histological subtypes of soft-tissue sarcoma.
  • In this review, we provide an overview of the literature concerning high-dose chemotherapy with hematopoietic stem cell support in the treatment of bone and soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Osteosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Neoplasms / drug therapy. Bone Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematopoietic Stem Cell Transplantation. Humans. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Male. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retrospective Studies. Skin Neoplasms / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15886503.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 35
  •  go-up   go-down


56. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prostheses and Implants. Prosthesis Implantation / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


57. Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, Hogendoorn P, Kroep J, Wass J, Athanasou N: Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer; 2010;10:462
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
  • GCTB frequently recurs and can produce metastatic lesions in the lungs.
  • METHOD: In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres.
  • Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues.
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Resorption. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteoclasts / drug effects. Osteoclasts / pathology. Treatment Outcome. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):35-51 [16311110.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Dent Res. 2007 Nov;86(11):1022-33 [17959891.001]
  • [Cites] Bone. 2008 Jan;42(1):68-73 [17962092.001]
  • [Cites] J Med Assoc Thai. 2008 Oct;91(10):1609-12 [18972907.001]
  • [Cites] Skeletal Radiol. 2009 Jan;38(1):5-9 [18649076.001]
  • [Cites] J Pain Symptom Manage. 2009 Aug;38(2):244-57 [19364633.001]
  • [Cites] Lancet Oncol. 2010 Mar;11(3):275-80 [20149736.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):945-54 [16153456.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):104-14 [10810467.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jan;(382):6-12 [11154006.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):54-6 [11196272.001]
  • [Cites] Ultrastruct Pathol. 2003 Nov-Dec;27(6):385-91 [14660277.001]
  • [Cites] Postgrad Med J. 2004 Apr;80(942):190-5 [15082837.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):103-9 [15346059.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] J Clin Pathol. 1990 Dec;43(12):997-1003 [2266187.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):465-71 [7526033.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Acta Orthop Scand. 1996 Jun;67(3):221-8 [8686457.001]
  • [Cites] Bone. 1996 Jan;18(1):9-14 [8717530.001]
  • [Cites] J Bone Miner Res. 1997 Oct;12(10):1746-52 [9333137.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:375-88 [9597160.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • (PMID = 20799989.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC2940802
  •  go-up   go-down


58. Folk GS, Williams SB, Foss RB, Fanburg-Smith JC: Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases. Head Neck Pathol; 2007 Sep;1(1):13-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing epithelioid fibrosarcoma (SEF) has distinctive morphology and occurs mainly in deep soft tissue of adult extremities.
  • Inclusion required OMFR location, an abundantly sclerotic sarcoma with epithelioid features, and lack of other phenotype by immunohistochemistry.
  • Tumor location included the infra-temporal fossa, buccal mucosa (recurrence extending into bone), anterior mandible (intraosseous primary, focally extending into soft tissue), and left parotid and submandibular gland (with metaplastic bone) regions.
  • Metastatic disease was present in 2 cases, to chest wall and lumbar/thoracic spine at 12 and 21 months, respectively.
  • [MeSH-major] Facial Bones / pathology. Fibrosarcoma / pathology. Maxilla / pathology. Mouth Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Apoptosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Female. Histiocytoma, Benign Fibrous / diagnosis. Humans. Leiomyoma / diagnosis. Male. Middle Aged. Sclerosis. Solitary Fibrous Tumors / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):127-31 [10867148.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):925-31 [2545330.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):699-709 [11395547.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):227-30 [12232581.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):90-4 [14693846.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 15;152(2):136-40 [15262433.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):410-3 [15322876.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):956-9; discussion 959-60 [11014436.001]
  • [Cites] Methods Enzymol. 1990;184:357-63 [1697021.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):979-93 [7661286.001]
  • [Cites] Histopathology. 1996 May;28(5):451-5 [8735721.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Histopathology. 1998 Oct;33(4):354-60 [9822926.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):102-6 [9844602.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Feb;114(2):87-9 [15757185.001]
  • [ErratumIn] Head Neck Pathol. 2013 Mar;7(1):103
  • (PMID = 20614275.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807507
  • [Keywords] NOTNLM ; Maxillofacial / Oral / Sarcoma / Sclerosing epithelioid fibrosarcoma
  •  go-up   go-down


59. Mavrogenis AF, Patapis P, Papaparaskeva KT, Galanis EC, Papagelopoulos PJ: Extraskeletal myxoid chondrosarcoma of the perineum. Orthopedics; 2009 Mar;32(3):216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraskeletal myxoid chondrosarcoma is an aggressive tumor with significant metastatic potential.
  • Extraskeletal myxoid chondrosarcoma is an unusual soft tissue sarcoma with ultrastructural and molecular features distinct from that of skeletal myxoid chondrosarcoma.
  • [MeSH-major] Chondrosarcoma / secondary. Perineum / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Disease-Free Survival. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymph Nodes / pathology. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Radiography, Thoracic. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309044.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. King DM, Hackbarth DA, Kilian CM, Carrera GF: Soft-tissue sarcoma metastases identified on abdomen and pelvis CT imaging. Clin Orthop Relat Res; 2009 Nov;467(11):2838-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcoma metastases identified on abdomen and pelvis CT imaging.
  • The current standard of care for patients with extremity soft-tissue sarcomas is to obtain imaging of the chest for staging and surveillance.
  • Our institutional standard of care has been to obtain CT scans of the chest, abdomen, and pelvis to evaluate for metastatic disease.
  • We retrospectively reviewed our sarcoma databases from 2000 to 2008.
  • We included 124 patients with 15 types of extremity soft tissue sarcomas evaluated with CT of the C/A/P.
  • Primary outcomes were (1) location of metastatic disease in relation to (2) sarcoma type.
  • Twenty patients (16%) presented with or developed abdomen/pelvis metastases and 10 of the 15 types of soft tissue sarcomas had abdominal or pelvic metastases.
  • A larger number of patients demonstrated metastatic disease in the abdomen and pelvis than anticipated.
  • We believe routine imaging of the abdomen and pelvic with CT for both staging and surveillance of all types of soft tissue sarcoma should be considered.
  • [MeSH-major] Pelvic Neoplasms / radiography. Sarcoma / secondary. Soft Tissue Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / radiography. Abdominal Neoplasms / secondary. Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Physiologic / methods. Neoplasm Staging. Registries. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):9-14 [10674442.001]
  • [Cites] Radiology. 2008 Jul;248(1):254-63 [18566177.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):289-91 [11461847.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Radiology. 2004 May;231(2):393-8 [15031431.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):328-32 [15187887.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):353-66 [3973646.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1120-7 [7850710.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Oncology (Williston Park). 1997 Sep;11(9):1327-32 [9306421.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):85-92 [9921978.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):389-95 [10023707.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):777-85 [10679646.001]
  • (PMID = 19636646.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2758993
  •  go-up   go-down


61. Stroppa E, Bertuzzi A, Di Comite G, Mussi C, Lutman RF, Barbato A, Santoro A: Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs; 2010 Dec;28(6):834-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
  • OBJECTIVE: The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas.
  • METHODS: Cohorts of four patients with metastatic soft tissue sarcomas received up to five cycles of intravenous ifosfamide 3000 mg/m2 on days 1- 3 in combination with escalating doses of intravenous Myocet on day 1 every 3 weeks until dose limiting toxicity (DLT) in at least one patient.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Feb;2(2):112-7 [6699662.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2869-79 [12767102.001]
  • [Cites] Sarcoma. 2000;4(1-2):31-5 [18521432.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Cancer Treat Rev. 2006 Feb;32(1):9-27 [16338075.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):239-46 [12634619.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1425-34 [10334527.001]
  • [Cites] Oncologist. 2003;8 Suppl 2:17-24 [13679592.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):231-3 [3882233.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Dec;54(6):514-24 [15322827.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3777-84 [18669466.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1527-34 [15367414.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1435-41 [10334528.001]
  • [Cites] Ann Intern Med. 1983 Dec;99(6):745-9 [6651020.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Aug;19(8):1097-104 [6352280.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):5-15 [15717735.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1609-18 [18518789.001]
  • [Cites] Cancer Treat Rev. 1993 Jul;19(3):197-228 [8334677.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2796-802 [8504422.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • (PMID = 19582371.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


62. Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H: Pulmonary metastasectomy in patients with soft tissue sarcomas: experiences in 50 patients. Thorac Cardiovasc Surg; 2006 Oct;54(7):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasectomy in patients with soft tissue sarcomas: experiences in 50 patients.
  • BACKGROUND: Pulmonary resection of metastatic soft tissue sarcomas is an accepted method of treatment.
  • METHODS: Between 1996 and 2001, 50 patients (27 men, 23 women) with pulmonary metastases from a soft tissue sarcoma underwent surgical resection.
  • CONCLUSION: We conclude that pulmonary resection of metastatic soft tissue sarcomas is a safe and effective treatment, which offers an improved survival benefit.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089318.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol; 2007 Jul;8(7):595-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies have suggested that trabectedin (ecteinascidin-743) could have antitumour activity in soft-tissue sarcoma.
  • In 17 of the 23 patients who achieved PR or CR as defined by RECIST and who had centralised radiological review, tissue-density changes, consisting of a decrease in tumour density on CT scan or a decrease in contrast enhancement on MRI (or both), preceded tumour shrinkage.
  • The noted patterns of tumour response were such that tissue density changes occurred before tumour shrinkage in several patients.
  • In some patients, tissue-density changes only were seen.
  • This analysis has resulted in the initiation of two prospective studies to assess the role of trabectedin in the treatment of patients with myxoid liposarcoma in preoperative and metastatic settings.
  • Furthermore, the selective mechanism of action for trabectedin in this translocation-related sarcoma is being studied.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Retrospective Studies. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Jul;8(7):565-7 [17613417.001]
  • (PMID = 17586092.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Oncogene Proteins, Fusion; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


64. Reis RM, Reis-Filho JS, Longatto Filho A, Tomarev S, Silva P, Lopes JM: Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors. Pathol Res Pract; 2005;201(12):771-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors.
  • Over the last few years, lymphatic vessels and lymphangiogenesis have received great attention owing to their putative implications in terms of metastatic dissemination and the promise of targets for lymphangiogenic therapy.
  • Here, we describe a double-immunostaining strategy for formalin-fixed, paraffin-embedded tissues that aims at evaluating the distribution of Prox-1 and CD 31 - a cytoplasmic pan-endothelial marker - in a series of 28 mucousae, cutaneous and soft tissue vascular lesions and tumors, including hemangiomas, lymphangiomas, lymphangiectasia, and Kaposi's sarcomas.
  • [MeSH-major] Antigens, CD31 / metabolism. Endothelial Cells / metabolism. Homeodomain Proteins / metabolism. Mucous Membrane / metabolism. Skin / metabolism. Soft Tissue Neoplasms / metabolism. Vascular Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / analysis. Child. Child, Preschool. Female. Hemangioma / metabolism. Humans. Immunohistochemistry. Infant. Infant, Newborn. Lymphangioma / metabolism. Lymphatic Vessels / metabolism. Male. Middle Aged. Sarcoma, Kaposi / metabolism. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308102.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers; 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


65. Ehlinger M, Gicquel P, Prévost P, Clavert JM, Kehr P, Simon P: [Clear-cell sarcoma of tendons and aponeuroses: three case reports]. Rev Chir Orthop Reparatrice Appar Mot; 2005 Oct;91(6):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear-cell sarcoma of tendons and aponeuroses: three case reports].
  • Clear-cell sarcoma (CCS) of tendons and aponeuroses is a rare malignant tumor representing about 1% of soft tissue tumors.
  • The tumor increases in size followed by metastatic dissemination to lymph nodes and the lungs.
  • This patient developed skin ulceration associated with paraplegia secondary to metastatic thoracic cord compression.
  • [MeSH-major] Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Child. Female. Foot / pathology. Hand / pathology. Humans. Male. Prognosis. Skin Ulcer / etiology. Spinal Cord Compression / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327694.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G: Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res; 2009 Aug;29(8):3281-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
  • BACKGROUND: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options.
  • CONCLUSION: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Immunoenzyme Techniques. Male. Melphalan / administration & dosage. Mesna / administration & dosage. Neoplasm Staging. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Neuroectodermal Tumors, Primitive, Peripheral / therapy. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Prospective Studies. Protective Agents / administration & dosage. Remission Induction. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Safety. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661346.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protective Agents; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


67. Lazar AJ, Das P, Tuvin D, Korchin B, Zhu Q, Jin Z, Warneke CL, Zhang PS, Hernandez V, Lopez-Terrada D, Pisters PW, Pollock RE, Lev D: Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res; 2007 Dec 15;13(24):7314-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.
  • PURPOSE: We examined a cohort of patients with alveolar soft part sarcoma (ASPS) treated at our institution and showed the characteristic ASPSCR1-TFE3 fusion transcript in their tumors.
  • In the three frozen samples subjected to an angiogenesis oligoarray, 18 angiogenesis-related genes were up-regulated in tumor over adjacent normal tissue.
  • CONCLUSION: ASPS is a highly vascular and metastatic tumor with a surprisingly favorable outcome; therapeutically resistant metastases drive mortality.
  • [MeSH-major] Neovascularization, Pathologic / genetics. Sarcoma, Alveolar Soft Part / genetics
  • [MeSH-minor] Adult. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094412.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASPSCR1 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TFE3 protein, human
  •  go-up   go-down


68. Brecht IB, Ferrari A, Int-Veen C, Schuck A, Mattke AC, Casanova M, Bisogno G, Carli M, Koscielniak E, Treuner J: Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer; 2006 Jan;46(1):11-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies.
  • Differently from adult oncologists that considered synovial sarcoma (SS) a tumor with uncertain chemosensitiveness, since two decades pediatric oncologists in Europe assumed that chemotherapy played an important role in SS treatment, so most pediatric patients were included in rhabdomyosarcoma protocols, receiving adjuvant chemotherapy regardless of risk factors.
  • No metastatic relapses occurred in Group I < or = 5 cm patients, while the outcome was poor for T2B patients (EFS 41%) due to a high rate of metastatic relapse.
  • [MeSH-major] Chemotherapy, Adjuvant. Radiotherapy, Adjuvant. Sarcoma, Synovial / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Germany / epidemiology. Humans. Infant. Italy / epidemiology. Male. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292743.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


69. Rong R, Doxtader EE, Tull J, de la Roza G, Zhang S: Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis. Int J Clin Exp Pathol; 2009;3(2):217-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis.
  • Poorly differentiated synovial sarcomas are diagnostically challenging soft tissue tumors.
  • Here we report a rare case of poorly differentiated metastatic synovial sarcoma to lung without known primary, diagnosed with molecular genetic analysis.
  • SYT-SSX gene fusion, characteristic for synovial sarcoma, was identified in this case by FISH and RT-PCR assays.
  • [MeSH-major] Lung Neoplasms / genetics. Lung Neoplasms / pathology. Sarcoma, Synovial / genetics
  • [MeSH-minor] Adult. Biopsy. Chromosomes, Human, Pair 18. Chromosomes, Human, X. Follow-Up Studies. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Male. Neoplasm Metastasis. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Translocation, Genetic

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 May;13(5):482-8 [10824918.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5859-66 [12384549.001]
  • [Cites] Hand Clin. 2004 Aug;20(3):325-33, vii [15275691.001]
  • [Cites] Am J Pathol. 1984 Oct;117(1):18-25 [6207733.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Jan;30(1):118-22 [1320707.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2156-67 [18563504.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jul;(364):220-6 [10416412.001]
  • [Cites] Curr Treat Options Oncol. 2005 Nov;6(6):449-59 [16242050.001]
  • [Cites] Mod Pathol. 2006 May;19(5):659-68 [16528378.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1199-207 [16879024.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2147-55 [18563503.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):673-82 [9630174.001]
  • (PMID = 20126590.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Repressor Proteins; 0 / SYT-SSX fusion protein; 164289-47-8 / synovial sarcoma X breakpoint proteins
  • [Other-IDs] NLM/ PMC2810002
  • [Keywords] NOTNLM ; Synovial sarcoma / lung / metastatic / molecular genetic
  •  go-up   go-down


70. Horvai AE, Kramer MJ, O'Donnell R: Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med; 2006 Jun;130(6):792-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study.
  • In synovial sarcoma (SS), aberrant beta-catenin expression has prognostic relevance, but the association with cyclin D1 has not been established.
  • OBJECTIVE: To determine whether nuclear beta-catenin is associated with cyclin D1 overexpression in SS and whether primary and metastatic SS differ in the expression of these markers.
  • DESIGN: We incorporated 82 tumors initially diagnosed as SS into a tissue array.
  • Primary and metastatic tumors were compared.
  • RESULTS: Fifty-one tumors (41 primary and 10 metastatic) from 43 patients demonstrated t(X;18).
  • Cyclin D1 staining was identified in 21 (59%) primary and 8 (80%) metastatic tumors, respectively, and nuclear beta-catenin in 24 (41%) primary and 7 (70%) metastatic tumors, respectively.
  • No significant difference was noted between primary and metastatic tumors with respect to the above markers.
  • [MeSH-major] Cyclin D1 / metabolism. Sarcoma, Synovial / metabolism. Soft Tissue Neoplasms / metabolism. Tissue Array Analysis. beta Catenin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / chemistry. Cell Nucleus / metabolism. Cell Nucleus / pathology. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, X / genetics. Extremities. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Survival Rate. Translocation, Genetic


71. Arnold PM, Roh S, Ha TM, Anderson KK: Metastatic synovial sarcoma with cervical spinal cord compression treated with posterior ventral resection: case report. J Spinal Cord Med; 2010;33(1):80-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic synovial sarcoma with cervical spinal cord compression treated with posterior ventral resection: case report.
  • CONTEXT: Synovial sarcomas, which represent 5% to 10% of all adult soft-tissue sarcomas, usually metastasize to the lungs.
  • Spinal cord compression due to spinal metastasis occurs in approximately 3% of patients with extraspinal soft-tissue sarcomas.
  • FINDINGS: A 26-year-old woman presented with neck pain, arm weakness, and a history of metastatic synovial sarcoma originating at the right knee.
  • CONCLUSION AND CLINICAL RELEVANCE: Metastatic spinal cord compression from synovial sarcoma is rare.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Sarcoma, Synovial / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2000 May;(374):247-58 [10818984.001]
  • [Cites] J Bone Joint Surg Br. 2008 Aug;90(8):1090-6 [18669969.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):797-801 [12185067.001]
  • [Cites] Laryngorhinootologie. 2004 Feb;83(2):96-101 [14999584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1468-73 [15050325.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] Clin Nucl Med. 1985 Apr;10(4):260-3 [2986892.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):35-44 [8383468.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1201-8 [8648375.001]
  • [Cites] Auris Nasus Larynx. 1999 Jan;26(1):91-4 [10077262.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2402-5 [16219854.001]
  • [Cites] J Neurosurg Spine. 2006 Feb;4(2):179-82 [16506487.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):E1339; discussion E1339 [17277671.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):105-13 [17592298.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):314-20 [18286474.001]
  • [Cites] Neurosurgery. 2001 Dec;49(6):1277-86; discussion 1286-7 [11846926.001]
  • (PMID = 20397449.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2853335
  •  go-up   go-down


72. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R: NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res; 2009 Jan;27(1):135-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients.
  • Enhanced expression levels of NG2 proteoglycan in presurgical original lesions of soft-tissue sarcoma (STS) patients defines with 55% probability the immediate (i.e., within 12 months postsurgery) risk in these individuals to develop postsurgical secondary lesions, independently of any other clinical trait.
  • Evaluation of the timing of metastasis formation in patients with high and low levels of NG2 in their primitive lesions further stratified the patients in subsets with diverse lag phases in the occurrence of metastatic disease.
  • In our cohort of high-grade STS cases, transcription of NG2 also showed a 81-fold amplification in metastatic lesions, when compared to primitive ones, and this gene overexpression was accompanied by an abundant but nonuniform in situ expression of its product.
  • In a similar manner as seen in primitive lesions, patients with higher levels of metastatic NG2 encountered a significantly more dismal clinical course.
  • Therefore, minimally invasive assessment of the transcription levels of the NG2 gene represents a parameter capable of predicting the arising of metastatic disease within a definite postsurgery time interval, and affords in adjunct in the definition of life expectance in STS patients.
  • [MeSH-major] Antigens / biosynthesis. Gene Expression Regulation, Neoplastic. Proteoglycans / biosynthesis. Sarcoma / metabolism. Sarcoma / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Transcription, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634019.001).
  • [ISSN] 1554-527X
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  •  go-up   go-down


73. Sanou R, Bazin C, Krakowski I, Boccaccini H, Mathias J, Beot S, Marchal F, Regent D: [Radiofrequency ablation for palliation of soft tissue tumor pain]. J Radiol; 2010 Mar;91(3 Pt 1):281-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation for palliation of soft tissue tumor pain].
  • PURPOSE: To assess the efficacy of radiofrequency (RF) ablation for palliation of soft tissue tumor pain.
  • MATERIALS AND METHODS: Retrospective study of 12 patients receiving palliative treatment for soft tissue tumors (5 primary tumors including 4 sarcomas and 1 PEComa and 7 metastatic tumors) with pain refractory to standard management.
  • CONCLUSION: Radiofrequency ablation for palliation of soft tissue tumor pain may be a useful complement to standard management.
  • [MeSH-major] Catheter Ablation / methods. Palliative Care. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analgesia. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Male. Middle Aged. Narcotics / administration & dosage. Pain / surgery. Pain Measurement. Perivascular Epithelioid Cell Neoplasms / surgery. Radiography, Interventional. Retrospective Studies. Sarcoma / secondary. Sarcoma / surgery. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20508558.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Narcotics
  •  go-up   go-down


74. Garcia JJ, Kramer MJ, Mackey ZB, O'Donnell RJ, Horvai AE: Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma. Arch Pathol Lab Med; 2006 Mar;130(3):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma.
  • CONTEXT: Clear cell sarcoma is a malignant soft tissue tumor with melanocytic differentiation.
  • Molecular methods are sometimes necessary to identify the unique t(12; 22)(q13;q12) translocation and differentiate clear cell sarcoma from melanoma.
  • OBJECTIVE: To determine whether CD117 immunoreactivity may be useful in separating melanoma from clear cell sarcoma.
  • DESIGN: We identified 20 tumors listed in our surgical pathology files that were diagnosed as clear cell sarcoma or in which clear cell sarcoma was strongly considered.
  • These were tested for the presence of the t(12;22) translocation by reverse transcriptase/polymerase chain reaction and sequencing from paraffin-embedded tissue.
  • Tumors with a t(12;22) translocation were immunostained with an antibody to CD117 and compared with 16 similarly stained metastatic melanomas.
  • No metastatic melanomas demonstrated t(12;22).
  • Conversely, 10 (63%) of 16 metastatic melanomas were, at least focally, positive for CD117; this difference was significant (P < .001).
  • Interestingly, 3 tumors in which clear cell sarcoma was initially considered as a diagnosis, but which lacked t(12;22), were also positive for CD117.
  • CONCLUSIONS: Reverse transcriptase/polymerase chain reaction, performed on paraffin-embedded tissue, is a useful, rapid tool for identifying the presence of t(12;22) in clear cell sarcoma.
  • The CD117 immunoreactivity may prove useful in the differential diagnosis of deep soft tissue or visceral lesions with melanocytic differentiation; positive staining results exclude clear cell sarcoma, but are compatible with metastatic melanoma.
  • [MeSH-major] Melanoma / diagnosis. Proto-Oncogene Proteins c-kit / analysis. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 22. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519562.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


75. Jain R, Grimer RJ, Carter SR, Tillman RM, Abudu AA: Outcome after disarticulation of the hip for sarcomas. Eur J Surg Oncol; 2005 Nov;31(9):1025-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eighty patients had disarticulation, of whom 46 had a bone sarcoma and 34 a soft tissue sarcoma.
  • In 38 patients the disarticulation followed local recurrence after unsuccessful limb salvage, three of these patients had palliative amputations already having metastatic disease.
  • CONCLUSION: Disarticulation of the hip remains a disabling procedure usually carried out for high grade sarcomas with extensive involvement of bone and soft tissues in the thigh.
  • [MeSH-major] Bone Neoplasms / surgery. Disarticulation. Hip / surgery. Leg. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157465.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, Bay JO, Mathoulin-Pelissier S, Coindre JM, Bui-Nguyen B: Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs; 2009 Oct;27(5):482-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
  • Multidrug chemotherapy increases responses in advanced soft tissues sarcoma.
  • Treatment with intensified MAID did not improve response rate neither survival and cannot be recommended for advanced or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):706-11 [16496406.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):267-72 [10362334.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1197-205 [18224666.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] Biometrics. 1987 Mar;43(1):213-23 [3567306.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2629-36 [7595717.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] N Engl J Med. 1988 Sep 8;319(10):593-8 [3045544.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 19148579.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


77. Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH: Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer; 2007 Oct 15;110(8):1815-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Myxoid liposarcoma (MLS) has an unusual tendency for extrapulmonary metastasis, particularly to the spine and soft tissues.
  • METHODS: Data from patients with had spinal metastases were obtained from the authors' institutional soft tissue sarcoma database.
  • The accuracy with which positron emission tomography (PET) scans and bone scans identified metastatic lesions was compared with the accuracy of magnetic resonance imaging (MRI).
  • [MeSH-major] Liposarcoma, Myxoid / secondary. Magnetic Resonance Imaging. Soft Tissue Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Predictive Value of Tests. Radiopharmaceuticals. Sensitivity and Specificity. Survival Rate


78. Kazakov DV, Zelger B, Rütten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M: Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol; 2009 May;33(5):705-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases harboring a sarcomatoid carcinoma featured a malignant epithelial component composed of varying combinations of BCAC-HG, BCAC-LG, IAC-NOS, or squamous cell carcinoma, whereas the sarcomatoid component appeared as either a pleomorphic or spindle-cell sarcoma.
  • Of the 21 patients with available follow-up (range, 3 mo-15 y; average 4.8 y; median 3.5 y), 10 were without evidence of disease, 1 was alive with metastatic disease, 1 was alive with BSS, 3 developed local recurrences, 4 had died of disease, and 2 were dead of other causes.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Australia. Carcinoma, Skin Appendage / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Chromosomes, Human, Pair 16. Europe. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Metaplasia. Middle Aged. Mutation. Neoplasm Invasiveness. South Africa. Syndrome. Treatment Outcome. Tumor Suppressor Proteins / genetics


79. Hartmann JT: Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs; 2007 Mar;18(3):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
  • Small round cell sarcoma, such as Ewing/PNET, desmoplastic small round cell sarcoma and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensitive and neoadjuvant protocols regardless of size or overt metastatic disease.
  • A limited number of effective agents available for the treatment of patients with metastatic adult soft-tissue sarcoma exists, which have failed anthracyline and ifosfamide-based chemotherapy.
  • Most other high-grade (grading >I) so-called adult-type soft-tissue sarcomas such as fibro, lipo, pleomorphic and synovial sarcoma are treated with a anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In this review, the therapeutic activities of drugs currently available as second-line treatment in patients with metastatic soft tissue sarcoma are summarized, providing an overview of contentious or emerging treatment issues.
  • In relapsed 'adult-type' soft-tissue sarcomas trofosfamide, gemcitabine and ecteinascidin (ET-743) appear to be drugs associated with moderate activity and an acceptable toxicity profile.
  • An interesting finding to be noted is that the different drugs have particular effects in distinct subtypes of soft-tissue sarcoma; however, it has to be taken into account that the number of patients included in those phase II trials are limited.
  • The so-called selective therapy targeting vascular endothelial growth factor (receptor), epidermal growth factor receptor, c-kit, Raf kinase or platelet-derived growth factor receptor and bcl-2 antisensing, proteasome, protein kinase C/B, and mammalian target of rabamycin inhibition will continue to be tested in gastrointestinal stromal tumors patients refractory to imatinib mesylate as well as in selected sarcoma subtypes.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264755.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Taxoids; 0 / Topoisomerase I Inhibitors; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 91
  •  go-up   go-down


80. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I: Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer; 2006 Sep;42(14):2303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
  • This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas.
  • In conclusion, this seems to be a feasible combination in patients with advanced soft tissue sarcomas, allowing ifosfamide to be given in a dosage similar to that used when given alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891112.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


81. Nair N, Basu S: Unsuspected metastatic male breast nodule from synovial sarcoma detected by FDG PET. Clin Nucl Med; 2005 Apr;30(4):289-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsuspected metastatic male breast nodule from synovial sarcoma detected by FDG PET.
  • Whole-body FDG PET imaging of a 24-year-old man with treated synovial sarcoma of the right upper extremity showed an abnormal focus of activity over the right chest in addition to abnormal uptake in the lungs.
  • Histopathology confirmed it to be metastasis from the synovial sarcoma.
  • [MeSH-major] Breast Neoplasms, Male / radionuclide imaging. Breast Neoplasms, Male / secondary. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Sarcoma, Synovial / radionuclide imaging. Sarcoma, Synovial / secondary. Soft Tissue Neoplasms / radionuclide imaging. Upper Extremity / radionuclide imaging
  • [MeSH-minor] Adult. Humans. Incidental Findings. Male. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764896.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Canter RJ, Qin LX, Downey RJ, Brennan MF, Singer S, Maki RG: Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Cancer; 2007 Nov 1;110(9):2050-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis.
  • BACKGROUND: The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial.
  • To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity.
  • CONCLUSIONS: Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Extremities / pathology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Perioperative Care. Pulmonary Surgical Procedures. Retrospective Studies. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy


83. Xie CF, Liu MZ, Xi M: Extraskeletal Ewing's sarcoma: a report of 18 cases and literature review. Chin J Cancer; 2010 Apr;29(4):420-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal Ewing's sarcoma: a report of 18 cases and literature review.
  • BACKGROUND AND OBJECTIVE: Extraskeletal Ewing's sarcoma (EES) is a rare, rapidly growing, round-cell, malignant tumor that can develop in the soft tissues at any location.
  • The presence of metastatic disease at the time of diagnosis and the mode of treatment were prognostic factors.
  • The presence of metastatic disease at the time of diagnosis and the mode of treatment are prognostic factors.
  • [MeSH-major] Sarcoma, Ewing / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Cell Adhesion Molecules / metabolism. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Lower Extremity. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Radiotherapy, High-Energy. Survival Rate. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346219.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Vimentin
  •  go-up   go-down


84. Le Péchoux C, Bonvalot S, Le Cesne A, Roberti E, Vanel D, Terrier P, Missenard G, Habrand JL: [Place and technical aspects of external beam radiation therapy in the treatment of adult soft tissue sarcomas]. Cancer Radiother; 2006 Feb-Mar;10(1-2):50-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Place and technical aspects of external beam radiation therapy in the treatment of adult soft tissue sarcomas].
  • In soft tissue sarcoma, surgical resection remains the cornerstone of therapy for localized disease.
  • Many retrospective studies and 2 randomized studies (one of adjuvant brachytherapy and one of external beam radiotherapy) have shown that adjuvant radiotherapy after complete surgery reduces significantly the risk of local recurrence in extremity soft tissue sarcomas.
  • Because of its rarity, and the risk of recurrence both local and metastatic, treatment should preferentially be discussed with a multimodality specialized approach.
  • [MeSH-major] Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380284.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 100
  •  go-up   go-down


85. Salemis NS, Gourgiotis S, Tsiambas E, Panagiotopoulos N, Karameris A, Tsohataridis E: Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor. J Gastrointest Cancer; 2010 Dec;41(4):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life occurring predominantly in the extremities.
  • CT scan revealed local tumor recurrence along with multiple pulmonary metastatic deposits.
  • CONCLUSIONS: Primary intra-abdominal MFH is a very rare but aggressive malignancy with a high tendency of local recurrence and metastatic spread.
  • [MeSH-major] Abdomen / pathology. Histiocytoma, Malignant Fibrous / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):499-505 [1845950.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2098-103 [1311983.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1299-302 [17451221.001]
  • [Cites] Gastrointest Radiol. 1988 Oct;13(4):299-305 [2844619.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Surg Today. 2003;33(10 ):794-6 [14513333.001]
  • [Cites] Surg Today. 2002;32(12):1091-5 [12541030.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] World J Gastroenterol. 2007 Dec 21;13(47):6441-3 [18081238.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Clin Imaging. 1998 Nov-Dec;22(6):408-13 [9876909.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Dig Surg. 1999;16(5):425-30 [10567806.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 22;3:15 [16792809.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):105-12 [16648661.001]
  • (PMID = 20419356.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Benassi MS, Ponticelli F, Azzoni E, Gamberi G, Pazzaglia L, Chiechi A, Conti A, Spessotto P, Scapolan M, Pignotti E, Bacchini P, Picci P: Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol Histopathol; 2007 09;22(9):1017-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
  • In recent years, classification of soft-tissue sarcomas (STS) has improved with cytogenetic analyses, but their clinical behavior is still not easily predictable.
  • Moreover, different levels of expression were related to histotype and metastatic phenotype.
  • [MeSH-major] Gene Expression. Plasminogen Activator Inhibitor 1 / metabolism. Sarcoma / metabolism. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cell Culture Techniques. Cell Line, Tumor. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Receptors, Urokinase Plasminogen Activator. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523079.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


87. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F: Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer; 2008 Jun;50(6):1147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma.
  • BACKGROUND: Recent technical advances in CT imaging and data processing have improved the ability to detect small pulmonary nodules in children with bone and soft-tissue sarcoma undergoing radiologic imaging of the chest.
  • PROCEDURE: We retrospectively studied medical records and CT chest scans at initial diagnosis of 210 children and young adults presenting to a single pediatric tertiary care hospital specialized in oncology for evaluation of bone or soft-tissue sarcoma.
  • Of patients who underwent biopsy or resection of a nodule, 41.7% had metastatic pulmonary disease.
  • Having more than three nodules and a bilateral distribution were associated with histology-proven metastasis (P = 0.002 and P = 0.011, respectively) and an increased frequency of recurrent or progressive metastatic disease in the lung (P < 0.001 and P = 0.023, respectively).
  • CONCLUSIONS: Pulmonary nodules were commonly detected during the initial evaluation of pediatric cases of sarcoma.
  • Number and distribution of nodules were significantly associated with metastatic disease and outcome.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Radiography, Thoracic. Sarcoma / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Solitary Pulmonary Nodule / radiography


88. Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ: Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol; 2009 Sep;35(9):994-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distant metastatic disease was more common in those with malignant histopathological findings (7/18 vs 1/15 p 0.046) and these patients were at increased risk of death (10/18 vs 0/15 p<0.01).
  • Those tumours with atypical or malignant features on histological examination have poor prognosis and should be managed and followed up in the same manner as other high-grade soft tissue tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. London. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345055.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Sternheim A, Jin X, Shmookler B, Jelinek J, Malawer MM: 'Telangiectatic' transformation in soft tissue sarcomas. a clinicopathology analysis of an aggressive feature of high-grade sarcomas. Ann Surg Oncol; 2008 Jan;15(1):345-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Telangiectatic' transformation in soft tissue sarcomas. a clinicopathology analysis of an aggressive feature of high-grade sarcomas.
  • BACKGROUND: 'Telangiectatic' change, which contains a large fluid hemorrhagic component, occurs in a variety of high-grade soft tissue sarcomas.
  • METHODS: In a retrospective database review, we identified 20 consecutive patients (3%) with 'telangiectatic' change in soft tissue sarcomas.
  • Histological diagnoses were MFH (40%), leiomyosarcoma (15%), synovial sarcoma (10%), and one each of seven other sarcomas (35%).
  • Of the patients, 15% presented initially with metastatic disease; in 53%, it developed within 2 years of diagnosis.
  • CONCLUSIONS: Telangiectatic transformation in soft tissue sarcomas is a rare feature of aggressive high-grade soft tissue sarcomas and is unique in its clinical presentation, MRI characteristics, pathological pattern, and a tendency for a worse-off prognosis.
  • [MeSH-major] Sarcoma / blood supply. Sarcoma / pathology. Telangiectasis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Soft Tissue Neoplasms / blood supply. Soft Tissue Neoplasms / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940825.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs; 2006 Sep;24(5):435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
  • BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins.
  • CONCLUSIONS: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Phosphorylcholine / analogs & derivatives. Sarcoma / drug therapy
  • [MeSH-minor] Academies and Institutes. Adult. Aged. Canada. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy


91. Pradhan A, Cheung YC, Grimer RJ, Peake D, Al-Muderis OA, Thomas JM, Smith M: Soft-tissue sarcomas of the hand: oncological outcome and prognostic factors. J Bone Joint Surg Br; 2008 Feb;90(2):209-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the hand: oncological outcome and prognostic factors.
  • We have investigated the oncological outcome of 63 patients with soft-tissue sarcomas of the hand managed at three major centres in the United Kingdom.
  • The three most common diagnoses were synovial sarcoma, clear cell sarcoma and epithelioid sarcoma.
  • We have shown that a clear margin of excision is essential to achieve local control of a soft-tissue sarcoma in the hand and that failure to achieve this results in a high risk of both local recurrence and metastatic disease.
  • [MeSH-major] Amputation / methods. Hand / surgery. Limb Salvage / methods. Neoplasm Recurrence, Local / prevention & control. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256090.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


92. Sharif MA, Hamdani SN: Second opinion and discrepancy in the diagnosis of soft tissue lesions at surgical pathology. Indian J Pathol Microbiol; 2010 Jul-Sep;53(3):460-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second opinion and discrepancy in the diagnosis of soft tissue lesions at surgical pathology.
  • OBJECTIVE: To determine the frequency and magnitude of discrepancies in the surgical pathological diagnosis of soft tissue lesions on review and second opinion in a histopathology center.
  • MATERIALS AND METHODS: All the cases of soft tissue as well as bone lesions, irrespective of age and gender, which were referred for second opinion or review after being reported elsewhere, were included in the study.
  • A panel of antibodies of soft tissue, epithelial and lymphoid markers was applied according to the requirements of each case.
  • RESULTS: During the study period, 34 cases of soft tissue lesions were received for review and second opinion.
  • All the cases in this category required immunohistochemistry as diagnosis of metastatic carcinoma was changed to sarcoma in two cases and diagnosis of sarcoma was changed to carcinoma in three cases.
  • [MeSH-major] Pathology, Surgical / methods. Referral and Consultation. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699503.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


93. Bahrami A, Folpe AL: Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol; 2010 Oct;34(10):1504-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period.
  • Adult-type fibrosarcoma (FS) was once considered the most common adult sarcoma, but is now considered a diagnosis of exclusion.
  • One hundred ninety-five cases diagnosed as adult FS in somatic soft tissue were retrieved from our institutional archives for the period 1960 to 2008.
  • Twelve patients (50%) died of locally aggressive and/or metastatic disease (median follow-up 1-year; range <1 to 8 y), 6 patients (25%) were alive without disease (median follow-up 11.5 y; range 2.5 to 35 y), and 6 patients (25%) died of other causes (median follow-up 10 y; range 9 to 18 y) ().
  • Non-FS (137 cases) were reclassified as: undifferentiated pleomorphic sarcoma (32 cases), SS (21 cases), solitary fibrous tumor (14 cases), myxofibrosarcoma (11 cases), malignant peripheral nerve sheath tumor (8 cases), FS dermatofibrosarcoma protuberans, and desmoplastic melanoma (4 cases each), low-grade fibromyxoid sarcoma, sarcomatoid carcinoma, desmoid-type fibromatosis, rhabdomyosarcoma, myofibroblastic sarcoma, spindle-cell liposarcoma (3 cases each), sclerosing epithelioid FS, fibroma-like epithelioid sarcoma, leiomyosarcoma, cellular fibrous histiocytoma (2 cases each), and others (17 cases).
  • Exclusive of undifferentiated pleomorphic sarcoma, the distinction of which from FS is subjective, 64% of putative FS were reclassified, most commonly as monophasic SS and solitary fibrous tumor.
  • We conclude that true FS is exceedingly rare, accounting for <1% of approximately 10,000 adult soft tissue sarcomas seen at our institution during this time period, and should be diagnosed with great caution.
  • [MeSH-major] Fibrosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Minnesota / epidemiology. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Repressor Proteins / metabolism. Young Adult


94. Ray-Coquard I, Le Cesne A, Whelan JS, Schoffski P, Bui BN, Verweij J, Marreaud S, van Glabbeke M, Hogendoorn P, Blay JY: A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist; 2008 Apr;13(4):467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
  • SUBJECTS AND METHODS: To establish the efficacy and safety of gefitinib in HER-1 - positive SyS refractory to one or two lines of doxorubicin- and ifosfamide-based chemotherapy, a phase II study was conducted from December 2002 to October 2005 by 12 centers of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  • All patients had previously received chemotherapy for metastatic disease, with a median number of two lines (range, 1-4).
  • The most frequent metastatic sites were the lungs (n = 44, 92%), lymph nodes (n = 11, 23%), and soft tissues (n = 10, 21%).
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Biomarkers, Tumor / analysis. Doxorubicin / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, ErbB-2 / analysis. Sarcoma, Synovial / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / analysis. Treatment Failure. Treatment Outcome


95. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol; 2007 Jul 20;25(21):3144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
  • PURPOSE: Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas.
  • PATIENTS AND METHODS: This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days.
  • CONCLUSION: Single-agent doxorubicin remains the treatment of choice for patients with advanced soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


96. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist; 2007 Nov;12(11):1351-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
  • The treatment outcome of patients with locally advanced and metastatic soft tissue sarcomas is poor.
  • This review addresses the clinical pharmacology, metabolism, and present role of ifosfamide in the treatment of locally advanced and/or metastatic soft tissue sarcomas, excluding gastrointestinal stromal tumors, the Ewing-like sarcomas, and other small blue round cell tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Ifosfamide / pharmacology. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Disease Progression. Doxorubicin / pharmacology. Drug Therapy / methods. Humans. Models, Biological. Neoplasm Metastasis. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055856.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 84
  •  go-up   go-down


97. Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, Michej W, Trepka S, Bylina E, Ruka W: Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg; 2010 Jun;36(6):868-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We included data from 459 consecutive patients treated from 1994 to 2007 with radical therapeutic lymph node dissection (LND; stage IIIB, C) due to clinically palpable and pathologically confirmed lymph node metastases (229 axillary; 230 ilioinguinal).
  • Established prognostic factors (number of metastatic nodes, p=.005; extracapsular extension of metastases, p=.002) influenced survival in the MUP group.
  • Thus, all MUP cases should be treated as standard stage III melanomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482725.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP: Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2010 Mar 15;76(4):1147-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
  • PURPOSE: Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas.
  • METHODS AND MATERIALS: We treated 34 patients (28 Stage III and 6 Stage IV) with locally advanced soft-tissue sarcomas of an extremity between 1995 and 2008.
  • The 5-year survival rate was 42.3% for all patients and 45.2% for Stage III patients.
  • The 5-year freedom-from-distant metastasis rate was 53.4% (Stage IV patients excluded), and freedom from distant metastasis was superior if treatment-induced tumor necrosis was 90% or greater (84.6% vs. 19.9%, p = 0.02).
  • The resulting treatment-induced necrosis rates are predictive of subsequent metastatic risk, and this information may provide an opportunity to guide postoperative systemic therapies.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 1993 Jun 1;71(11):3685-9 [8490918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):259-65 [8407399.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):908-15 [14624787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1096-103 [11378339.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Cancer. 2008 Jun;112(11):2432-9 [18348295.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):646-53 [15965732.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • (PMID = 19577863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124557-01A1; United States / NCI NIH HHS / CA / R21 CA124557; United States / NCI NIH HHS / CA / R21 CA124557-01A1
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS230212; NLM/ PMC2931332
  •  go-up   go-down


99. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


100. Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W: Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit; 2007 Nov;13(11):CR515-522
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL/METHODS: The clinico-pathological and genetic factors influencing disease-free survival (DFS) in 335 patients with primary CD117-immunopositive tumors (group A; calculated from primary tumor resection) and progression-free survival (PFS) in 232 metastatic/unresectable GIST patients treated with IM (group B; calculated from the start of imatinib therapy) were analyzed.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Child. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Multivariate Analysis. Mutation. Prognosis. Prospective Studies. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968300.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down






Advertisement